Orforglipron

What it is

Orforglipron activates the GLP-1 receptor, the same target as injectable drugs built on a natural gut hormone that slows digestion, curbs appetite, and helps the body release insulin. What sets it apart is chemistry: it is a small molecule built without amino acids, so it survives digestion and can be taken as a tablet instead of a shot.

Papers describing its action call the effect biased signaling: it favors one internal signaling path over another in a way researchers think reduces how quickly cells stop responding to the drug. Bioavailability and half-life figures reported for the compound support once-a-day use without needing food or water restrictions.

How it is studied

The evidence for orforglipron comes entirely from human Phase 3 trials rather than animal or cell studies, since the compound moved through drug development toward an FDA decision. Trials measured body weight, blood sugar (HbA1c), and cardiovascular markers such as blood pressure and triglycerides over periods of 40 to 72 weeks in adults with obesity, with or without type 2 diabetes.

What studies report

• In a 72-week trial of adults with obesity but not diabetes, the highest amount studied (36 mg a day) was linked to an average weight loss of about 11 percent, compared with about 2 percent on a placebo, a dummy pill with no active drug. [1]
• In a separate 72-week trial in people with both obesity and type 2 diabetes, the highest amount tested was linked to about 9.6 percent average weight loss, compared with about 2.5 percent on placebo. [2]
• Over 40 weeks in adults with early type 2 diabetes, every amount tested lowered HbA1c, a blood test that reflects average blood sugar, by roughly 0.8 to 1.1 percentage points more than placebo, bringing average blood sugar readings down to about 6.5 to 6.7 percent. [3]
• Across all three trials, measures linked to heart and metabolic health, including waist size, blood pressure, and blood fat levels, improved more with orforglipron than with placebo. [1][2]

What is not known

Orforglipron only recently finished Phase 3 testing, so there is no independent long-term safety record outside the trials that supported its approval. Two of the three main trials compared it only against placebo rather than against an approved injectable GLP-1 drug in the same study, so how its effects compare head to head against those drugs is still an open question in the trials reviewed here.

Reported adverse findings

• Across all three trials, the most common side effects were mild to moderate digestive symptoms such as nausea and diarrhea, most occurring while the amount taken was being raised step by step toward its target level. [1][2][3]
• Between about 4 and 10 percent of people taking orforglipron stopped the drug because of side effects, compared with about 1 to 4 percent of people on placebo. [1][2][3]

Regulatory status

Orforglipron, marketed under the brand name Foundayo, received FDA approval in April 2026 as an oral tablet for chronic weight management in adults, reviewed under the agency's National Priority Voucher program. It is available only by prescription. The Phase 3 diabetes trial summarized here supported the drug's blood sugar effects but the approval described in the reviewed record is specific to weight management; researchers should not assume a separate diabetes approval without checking current prescribing information.